Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Imaging And Path LabBOM:544482 +5.54%22 Return-on-Tangible-Asset is 12.17% as of Mar. 2026, which is 21% below its 10-year median of 15.40. GuruFocus rates BOM:544482 with a GF Score™ of 22/100. Among 213 Medical Diagnostics & Research companies, Star Imaging And Path Lab ranks better than 85.92% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Star Imaging And Path Lab's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹184.6 Mil. Star Imaging And Path Lab's average total tangible assets for the quarter that ended in Mar. 2026 was ₹1,516.8 Mil. Therefore, Star Imaging And Path Lab's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 12.17%.
The historical rank and industry rank for Star Imaging And Path Lab's Return-on-Tangible-Asset or its related term are showing as below:
BOM:544482'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 0.98 Med: 15.4 Max: 17.99
Current: 14.42
During the past 5 years, Star Imaging And Path Lab's highest Return-on-Tangible-Asset was 17.99%. The lowest was 0.98%. And the median was 15.40%.
BOM:544482's Return-on-Tangible-Asset is ranked better than 85.92% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.83
vs BOM:544482: 14.42
Star Imaging And Path Lab (BOM:544482) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Star Imaging And Path Lab Return-on-Tangible-Asset Related Terms
Star Imaging And Path Lab Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Star Imaging And Path Lab's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Imaging And Path Lab Return-on-Tangible-Asset Chart
BOM:544482 vs TMO, DHR, NTRA: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Star Imaging And Path Lab's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Imaging And Path Lab Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Star Imaging And Path Lab's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Star Imaging And Path Lab's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 12.17% mean?
Star Imaging And Path Lab (BOM:544482) has a Return-on-Tangible-Asset of 12.17% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Star Imaging And Path Lab and its competitors. This is 21% below median its historical median of 15.40. Over the past decade, Star Imaging And Path Lab's Return-on-Tangible-Asset has ranged from 0.98 to 17.99. According to the industry distribution chart, Star Imaging And Path Lab ranks #30 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 14.1%.
Is Star Imaging And Path Lab's Return-on-Tangible-Asset too high?
Star Imaging And Path Lab's current Return-on-Tangible-Asset of 12.17% is 21% below median its 10-year median of 15.40. Over the past 10 years, this metric has ranged from a low of 0.98 to a high of 17.99. Based on the distribution chart, Star Imaging And Path Lab ranks #30 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Star Imaging And Path Lab has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Star Imaging And Path Lab's Return-on-Tangible-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Star Imaging And Path Lab ranks #30 out of 213 companies for Return-on-Tangible-Asset. This places Star Imaging And Path Lab in the top 14% of its industry — outperforming the majority of peers. Historically, Star Imaging And Path Lab's own Return-on-Tangible-Asset has ranged from 0.98 to 17.99 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Star Imaging And Path Lab and its competitors. Star Imaging And Path Lab's current Return-on-Tangible-Asset is 12.17%, which is 21% below median its own 10-year median of 15.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Imaging And Path Lab stock overvalued right now?
Star Imaging And Path Lab (BOM:544482) has a current Return-on-Tangible-Asset of 12.17%. The current Return-on-Tangible-Asset is 12.17%, which is 21% below median its 10-year median of 15.40. Star Imaging And Path Lab's overall GF Score™ is 22/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Star Imaging And Path Lab (BOM:544482), the current Return-on-Tangible-Asset is 12.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Star Imaging And Path Lab Ltd operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi and Uttar Pradesh. It offers a comprehensive range of diagnostic imaging services and clinical laboratory tests, including both routine and specialized studies and profiles. These services are essential for the prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. The company's diagnostic imaging and radiology services encompass X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, ultrasounds, bone mineral densitometry, and mammography.
22GF Score
Get the complete analysis for BOM:544482
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544482 has been successfully added to your 
